In collaboration with Dr Jo Perry from the Liggins Institute and Dr Jack Flanagan we are endeavouring to identify small molecules which inhibits oncogenic growth hormone receptor signalling in human breast tumours. The growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis is emerging as an important mediator of tumour development. We are looking for small molecule antagonists which bind to the human growth hormone receptor (hGHR) and prevent activation of human growth hormone (hGH)-mediated signal transduction.
